Anticancer Drugs

Edited by
October 2019
214 pages
  • ISBN978-3-03921-586-7 (Paperback)
  • ISBN978-3-03921-587-4 (PDF)

This book is a reprint of the Special Issue Anticancer Drugs that was published in

Biology & Life Sciences
Chemistry & Materials Science
Medicine & Pharmacology

The past decades have seen major developments in the understanding of the cellular and molecular biology of cancer. Significant progress has been achieved regarding long-term survival for the patients of many cancers with the use of tamoxifen for treatment of breast cancer, treatment of chronic myeloid leukaemia with imatinib, and the success of biological drugs. The transition from cytotoxic chemotherapy to targeted cancer drug discovery and development has resulted in an increasing selection of tools available to oncologists. In this Special Issue of Pharmaceuticals, we highlight the opportunities and challenges in the discovery and design of innovative cancer therapies, novel small-molecule cancer drugs and antibody–drug conjugates, with articles covering a variety of anticancer therapies and potential relevant disease states and applications. Significant efforts are being made to develop and improve cancer treatments and to translate basic research findings into clinical use, resulting in improvements in survival rates and quality of life for cancer patients. We demonstrate the possibilities and scope for future research in these areas and also highlight the challenges faced by scientists in the area of anticancer drug development leading to improved targeted treatments and better survival rates for cancer patients.

  • Paperback
License and Copyright
© 2019 by the authors; CC BY-NC-ND license
antibody; drug conjugation; chemical linker; drug delivery; and cancer therapy; P450c17; prostate cancer; abiraterone; steroidogenesis; androgens; dehydroepiandrosterone; CYP17A1; cytochrome P450; anti-cancer drugs; DSD; cyclooxygenase-1; cyclooxygenase-2; cancer; inflammation; tumorigenesis; COX-1 inhibitor; [18F]FDG PET/CT; biomarker profiling; cancer; oesophageal cancer; treatment resistance; cisplatin; metabolism; inflammation; radiation; intestinal mucositis; heteropolysaccharide; 5-fluorouracil; inflammation; Combretastatin A-4; β-lactam; 3-vinylazetidin-2-ones; antiproliferative activity; tubulin; antimitotic; magnetic targeting; graphene oxide; maghemite; glioblastoma; cisplatin; ellipticine; anticancer; heterocyclic chemistry; indole; NCI screen; topoisomerase II; snticancer drugs; cancer drug design; cancer immunotherapy; conjugate and hybrid drugs, cisplatin resistance, topoisomerase inhibitors; microtubule targeted drugs